Topic:

M&A

Latest Headlines

Latest Headlines

'Unpromising' Allergan drug projects headed for the chopping block--report

Allergan execs have made no secret of the fact that they've been planning to come up with a lean-and-mean game plan designed to prove to investors that they'd be much better off if they spurned Valeant's offer to buy the company and gut its R&D division. Citing sources close to the company,  Bloomberg  is reporting that the cutbacks should include work on its most "unpromising" programs in the pipeline.

Actavis cans 190 Forest workers while 6 execs share up to $186M in deal 'awards'

There are winners and losers in mergers, and as a general rule, executives win and at least some workers lose. That certainly is the case with Actavis and Forest Laboratories. While nearly 200 Forest employees in the St. Louis, MO, area got pink slips this week, top execs will receive up to $186 million in "merger success awards" for closing the $25 billion deal.

International brouhaha over AbbVie misstep highlights U.K.'s M&A rules

Analysts generally believe that big takeovers are easier to pull off under the U.K.'s M&A guidelines. But you'd better not ignore the very specific rules of the game. AbbVie got a lesson on that score yesterday after CEO Richard Gonzalez confidently confided to a number of major news outlets, including the Financial Times and Reuters, that he had already chatted up most of Shire's big investors and won their support for a $51 billion buyout.

NIH sickle cell partner AesRx moves up the food chain in Baxter buyout

Having played a pioneering role collaborating with the NIH on a new drug for sickle cell disease, Newton, MA-based AesRx has moved up the food chain after completing a buyout deal with Baxter International.

Salix picks up Cosmo's Irish unit for $2.7B and a lower tax bill

Yet another U.S. company is orchestrating a deal that will allow it to move overseas and slash its tax rate. Salix Pharmaceuticals of North Carolina says it will merge with an Ireland-based unit of Cosmo Pharmaceutical and buy out some of its patents for drugs to treat gastrointestinal diseases for $2.7 billion in stock.

U.K. CRO emerges from $100M in deals with plans for more M&A

With the help of U.K. investor Equistone, newly minted CRO Concept Life Sciences has snapped up three contractors and set out to do business as a conglomerate, scouting for clients looking to outsource scientific work.

Belgium's Omega Pharma may be the next seller in OTC deal wave

Lately, OTC businesses have been selling like hotcakes, with a number of global consumer players looking to bulk up. Now, reports say Belgium's Omega Pharma could be the next to enter the deal arena with an OTC business worth more than $4 billion.

AbbVie puts $51.5B on the table in fourth go at Shire

After three failed bids for Shire, AbbVie's hoping the fourth will be the charm. The Abbott spinoff has sweetened its offer, upping its price to £30.1 billion ($51.5 billion) to lure the Irish drugmaker to the bargaining table.

UPDATED: Intent on closing a deal, AbbVie boosts its bid for Shire to $51B

Intent on nailing a big Shire buyout, this morning AbbVie boosted its premium offer by 11%, bringing the total to some $51 billion.

Ulthera device clears FDA for décolleté on heels of Merz acquisition plans

Merz already committed to buying Ulthera for up to $600 million in cash and milestones. Now it will get another FDA-cleared indication as part of the bargain. The company's system has cleared the FDA to improve the lines and wrinkles of the décolleté.